ETOPOSIDE
T-Cell Acute Lymphoblastic Leukemia
University of WashingtonSmall moleculePhase 3Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 55/ 100
- Competitive Position
- 73/ 100
Competitive context
75 Active assets in the T-Cell Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Children's Oncology Group | Phase 3 | BB |
Daunorubicin SWOG Cancer Research Network | Phase 3 | BB |
PEGASPARGASE Children's Oncology Group | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS SWOG Cancer Research Network | Phase 3 | BB |
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) University of Washington | Phase 3 | BB |
View all 50 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →